Background: Multidrug-resistant (MDR) Acinetobacter baumannii infections have high mortality rates and few treatment options. Synergistic drug combinations may improve clinical outcome and reduce further emergence of resistance in MDR pathogens. Here we show an unexpected potent synergy of two translation inhibitors against the pathogen: commonly prescribed macrolide antibiotic azithromycin (AZM), widely ignored as a treatment alternative for invasive Gram-negative pathogens, and minocycline, among the current standard-of-care agents used for A. baumannii. Methods: Media-dependent activities of AZM and MIN were evaluated in minimum inhibitory concentration assays and kinetic killing curves, alone or in combination, both in standard bacteriologic media (cation-adjusted Mueller-Hinton Broth) and more physiologic tissue culture media (RPMI), with variations of bicarbonate as a physiologic buffer. Synergy was calculated by fractional inhibitory concentration index (FICI). Therapeutic benefit of combining AZM and MIN was tested in a murine model of A. baumannii pneumonia. AZM + MIN synergism was probed mechanistically by bacterial cytological profiling (BCP), a quantitative fluorescence microscopy technique that identifies disrupted bacterial cellular pathways on a single cell level, and real-time kinetic measurement of translation inhibition via quantitative luminescence. AZM + MIN synergism was further evaluated vs. other contemporary high priority MDR bacterial pathogens. Findings: Although two translation inhibitors are not expected to synergize, each drug complemented kinetic deficiencies of the other, speeding the initiation and extending the duration of translation inhibition as verified by FICI, BCP and kinetic luminescence markers. In an MDR A. baumannii pneumonia model, AZM + MIN combination therapy decreased lung bacterial burden and enhanced survival rates. Synergy between AZM and MIN was also detected vs. MDR strains of Gram-negative Klebsiella pneumoniae and Pseudomonas aeruginosa, and the leading Gram-positive pathogen methicillin-resistant Staphylococcus aureus. Interpretation: As both agents are FDA approved with excellent safety profiles, clinical investigation of AZM and MIN combination regimens may immediately be contemplated for optimal treatment of A. baumannii and other MDR bacterial infections in humans.
Introduction
The emergence and spread of antibiotic resistant bacterial pathogens impose considerable morbidity and mortality on the healthcare system.
As our arsenal of previously efficacious antibiotics dwindle, so too does our capacity to successfully treat patients infected with multidrugresistant (MDR) bacterial pathogens. Among these, the Gram-negative coccobacillus Acinetobacter baumannii is of foremost concern in hospital-acquired infections such as ventilator-associated pneumonia, bacteremia, and urinary tract infection [1] [2] [3] , and as a cause of serious wound infections among military personnel in the Iraq and Afghanistan wars [4] . A. baumannii is intrinsically resistant to many EBioMedicine 46 (2019) [193] [194] [195] [196] [197] [198] [199] [200] [201] antibiotics and rapidly acquires additional drug resistance [5] , with approximately two-thirds of hospital-acquired A. baumannii infections in the U.S. now classified as MDR [6] . Importantly, MDR strains of A. baumannii have higher associated mortality rates than drugsusceptible strains [7] .
One key strategy for combating MDR pathogens is by thoughtful implementation of combination therapies, involving action on multiple targets whose combined effects increase the potency of the treatment. Multidrug therapies are predicated on drug-drug interactions instead of novel compounds, and can help reduce the evolution of resistance, since more resistance conferring adaptions are required than in monotherapy. Such therapies have been successful against a variety of difficult to treat bacterial infections (e.g. Mycobacterium tuberculosis) where multi-drug therapy is still efficacious despite its implementation over three decades ago [8] . Indeed, in the current era of antibiotic resistance, a number of unappreciated and underutilized drug are receiving new consideration as components of combination therapy vs. MDR pathogens [9] .
Recently, we reported unanticipated bactericidal activity for azithromycin (AZM) against several MDR Gram-negative rods (GNR) including A. baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa that is not recognized by standard antimicrobial testing paradigms [10] . While AZM is the most commonly prescribed antibiotic in the U.S., it is not currently recommended nor utilized for serious GNR infections because of absent activity in cation-adjusted Mueller-Hinton broth (CA-MHB), the standard for antimicrobial susceptibility testing (AST) adopted by the Clinical Laboratory Standards Institute (CLSI) in the U.S. and the European Committee on AST (EUCAST). However, we recently showed AZM has excellent activity when AST is performed instead in a mammalian tissue culture type media, Roswell Park Memorial Institute 1640 media (RPMI). Furthermore, AZM synergizes strongly with host immune factors such as the cationic defense peptide cathelicidin and serum complement, or with the peptide antibiotic colistin, ultimately exerting a clear therapeutic effect in murine models of pneumonia with A. baumannii, K. pneumoniae and P. aeruginosa [10] .
A reintroduction of AZM into the clinical arsenal to treat high-priority MDR pathogens such as A. baumannii will certainly involve its incorporation into combination therapy regimens. Intravenous administration of minocycline (MIN) has emerged as an important antibiotic treatment option for serious MDR A. baumannii infections, particularly nosocomial pneumonia, and is currently considered a standard-of-care [11, 12] . While precious few antibiotics are still effective against MDR A. baumannii, 79.1% of clinical strains remain susceptible to MIN [13] , and along with the potentially nephrotoxic colistin, MIN represents one of the last lines of defense against the pathogen. Ideally, MIN would be combined in an efficacious multi-drug therapeutic approach, thereby preserving its current activity and protecting its clinical longevity.
Despite both agents targeting the bacterial ribosome to inhibit protein synthesis at the translational level, we here report the discovery of an unexpected synergistic interaction between AZM and MIN against MDR A. baumannii in AST and a murine pneumonia model in vivo. The two agents exhibit different patterns of media-dependent bactericidal activity and translation inhibition kinetics that may reinforce one another to provide a rapid and sustained antibiotic effect against A. baumannii and other high-priority MDR pathogens.
Methods

Bacterial strains
Drug-sensitive A. baumannii strain ATCC-17978 was obtained from the American Type Culture Collection (ATCC). MDR virulent A. baumannii strain AB5075, isolated from a patient with tibial osteomyelitis [14] , was acquired from the Walter Reed Medical Center. MDR A. baumannii strains GNR175J and GNR0717, as well as MDR strains of K. pneumoniae (K1100) and P. aeruginosa (P4), are all recent clinical isolates from a tertiary academic hospital in New York [10, 15] . Communityacquired MRSA USA300 strain TCH1516 was isolated from an adolescent patient at Texas Children's Hospital [16] . MDR A. baumannii strain AB5075-luxCDABE was constructed via insertion of the Tn7-luxCDABE mini-Tn7 element (obtained from D. Zurawski, Walter Reed Army Medical Center) into the attTn7 site in AB5075 by described methods [14, 17] .
Antibiotics
MIN (Rempex Pharmaceuticals) and AZM (Fresenius Kabi) were purchased from a clinical pharmacy and resuspended in 1× Dulbecco's phosphate-buffered saline (DPBS) (Corning). Concentrated stocks of AZM were prepared at 100 mg/ml and MIN at 20 mg/ml. Fresh 10× or 20× experimental stocks of AZM and MIN were made in 1× DPBS at the desired concentration prior to the start of each experiment.
Reagents and bacterial culturing conditions
Bacterial strains for antibiotic susceptibility testing were first streaked on LB agar (LA) plates from stocks stored at −80°C (in 20%
Research in context
Evidence before this study Acinetobacter baumannii is a frequently multidrug-resistant (MDR) nosocomial pathogen causing pneumonia, bacteremia, and wound infections with high associated mortality rates. Among the last defenses against MDR A. baumannii is minocycline (MIN), which ideally would be combined in an efficacious multi-drug therapy for optimal cure rates and preservation of clinical longevity. In an earlier eBiomedicine study, we reported unanticipated bactericidal activity of azithromycin (AZM) in vitro and in vivo against MDR Gram-negative pathogens including A. baumannii, not recognized by standard antimicrobial testing paradigms. Currently, AZM is neither recommended nor utilized for serious GNR infections.
Added value of this study AZM activity against MDR A. baumannii is revealed upon testing in more physiologic media (e.g. tissue culture media) and with bicarbonate present as a physiologic buffer. Although AZM and MIN are both translation inhibitors and not predicted to synergize, each drug complemented kinetic deficiencies of the other, speeding the initiation and extending the duration of translation inhibition as calculated by fractional inhibitory concentration index (FICI). Synergy of the two drugs was verified morphometrically by fluorescencebased bacterial cytological profiling and a real time assay of translation efficiency. AZM + MIN combination therapy decreased lung bacterial burden and enhanced survival rates in a murine pneumonia model, verifying in vivo relevance. AZM and MIN synergy was further documented against additional high priority MDR pathogens.
Implications of all the available evidence
Our evaluation of the best antibiotic options to treat the highest priority MDR pathogens is hamstrung by the narrowness of the current testing paradigm. Since AZM is widely prescribed and has an excellent safety profile, clinical studies adding AZM to current standard-of-care MIN could immediately be contemplated for patients suffering MDR A. baumannii infections, with a potential to reduce unacceptably high morbidity and mortality rates.
glycerol/80% MHB) and grown to stationary phase at 37°C overnight. Isolated colonies were picked from the plate and inoculated into 5 ml of either CA-MHB (MHB (Difco) supplemented with 20 μg/ml Ca 2+ and 10 μg/ml Mg 2+ ) or RPMI+ (phenol free RPMI (Gibco 1640) + 10% LB (Criterion)) media in a 14 ml Falcon polypropylene roundbottom snap cap tube (Corning #352059) and grown shaking at 100 rpm overnight at 37°C. The following day, overnight cultures were sub-cultured 1:50 in the desired medium and volume in either 14 ml snap cap tubes or 50 ml polypropylene conical tubes (Corning #352098) and grown shaking at 100 rpm at 37°C until midlogarithmic phase (~OD 600 = 0.4). Unless otherwise noted, experiments were conducted in Costar flat-bottom 96 well plates (Corning #3370) with a final volume of 200 μl/well.
MIC determination
Bacteria were cultured in the same media throughout (CA-MHB or RPMI+) prior to the addition of antibiotics. Mid-logarithmic phase cultures were diluted to approximately 5 × 10 5 CFU (~OD 600 = 0.002) and 180 μl added to each experimental well of a 96 well flat bottom plate. Either 20 μl of 1xDPBS or 20 μl of the desired 10× drug stock were added to each well. Plates were incubated shaking at 100 rpm at 37°C overnight. Bacterial growth (OD 600 ) was determined approximately 20 h later with an Enspire Alpha multimode plate reader (PerkinElmer). To calculate the MIC 90 , defined as the amount of drug required to inhibit ≥90% of the growth of the untreated controls, the density of each drug-treated well was compared to untreated control. Determination of synergy was performed in the same manner except combinations of AZM and MIN were examined using checkerboard assays, where 10 μl from 20× stocks of each drug were added to each well so that the ratio of media to drugs remained consistent to the monotherapy MIC experiments. Fractional inhibition concentrations (FIC) were determined for each drug in combination and a fractional inhibition concentration index (FICI) value was calculated. Synergy was defined as an FICI value ≤0.5 [18] .
Bactericidal activity assays
A. baumannii AB5075 was cultured in CA-MHB for both the overnight and the next day mid-logarithmic cultures. The latter was used to inoculate 15 ml of either CA-MHB, RPMI+, or 80% RPMI +20% fresh human whole blood with approximately 5 × 10 5 CFU (~OD 600 = 0.002). The venous blood was collected in small samples from healthy volunteers under a simple phlebotomy protocol approved by the University of California, San Diego (UCSD) Institutional Review Board. Each experimental well of the 96-well flat bottom plate received 180 μl of bacterial culture and 20 μl of the desired 10× drug stock. Plates were incubated shaking at 100 rpm at 37°C overnight. After 20 h, plates were removed from the incubator and serial 10-fold dilutions of each well performed in CA-MHB. Twenty microlitres of each serial dilution was spot plated onto LA and incubated at 37°C overnight to enumerate the CFU.
Mouse pneumonia model
All animal experiments were conducted under veterinary supervision and approved by the UCSD IACUC. A. baumannii AB5075 was grown in CA-MHB as described for the bactericidal activity experiments. Mid-logarithmic phase cultures were centrifuged at 3202 xg, supernatant removed, and pellets resuspended and washed in an equal volume of 1×DPBS three times, before the final pellet was resuspended in 1× DPBS to yield a culture of 2.5 × 10 9 CFU/ml.
For in vivo studies, all mice were housed in an SPF barrier facility on a 12/12 light/dark cycle in Innovive Innocage pre-bedded corn cob disposable cages on a 2020× diet from Envigo. Mice were randomized at least 48 h prior to infection by the UCSD vivarium staff (blind to the researcher) into groups of 5 mice for the survival studies; additional groups of 2-3 randomized mice were added for lung enumeration studies. No more than 5 mice were housed within the same cage and no cage contained mice from different groups. No differences in the relevant health statuses of the groups were present prior to the infection and no unexpected adverse events occurred beyond lethargy and mortality due to the infections. All animals were included in the analysis.
Forty microlitres of the resuspended culture was used to intratracheally infect 8-week-old juvenile female C57Bl/6 J mice (Jackson Labs) under 100 mg/kg ketamine (Koetis) + 10 mg/kg xylazine (VetOne) anesthesia using an operating otoscope (Welch Allyn) between 2 and 4 PM PT as previously described [10] . Post-infection, mice were allowed to recover on a sloped heated pad and then returned to their home cage. At 1 h and 24 h post-infection, the mice were treated with 100 μl of either AZM (sub-cutaneous injection) or MIN (inter-peritoneal injection) at the desired drug concentrations. AZM and MIN doses were reconstituted in 1× DPBS (Corning) and pre-loaded into 1 cc U-100 insulin syringes (Becton Dickinson). For survival experiments, mice were monitored for a total of 6 days. Surviving mice were euthanized at 6 days post-infection through CO 2 exposure followed by cervical dislocation. For lung CFU enumeration studies, mice were euthanized 30 h post-infection under the same euthanasia procedure, all 5 lung lobes removed, and the tissues placed into a 2 ml sterile microtube (Sarstedt) containing 1 mm silica beads (Biospec) and 1 ml 1×DPBS. The tissue samples were homogenized for 1 min on a MagNA Lyser (Roche), followed by 1 min on ice x 3, then 10-fold serially diluted, plated on LA plates, and grown and incubated overnight for CFU determination.
Bacterial cytological profiling
Fluorescence microscopy was performed as previously described [19] with modifications. In brief, AB5075 was grown in CA-MHB or RPMI+ at 37°C to a starting OD 600~0 .13 and then treated with appropriate concentrations of MIN, AZM, or combination of both antibiotics for 2 h at 37°C. After treatment, cells were stained with 10 μg/ml FM4-64, 4 μg/ml DAPI, and 0.5 μM SYTOX-Green. Samples were transferred to a glass slide containing an agarose pad (1.2% agarose in 20% CA-MHB or RPMI+) for microscopy. Image analysis was done using FIJI (ImageJ 1.51w).
Translational activity assays
Strain AB5075-luxCDABE contains the full luciferase cassette and is therefore capable of constituently producing both the enzyme and substrate required for luminescence. AB5075-luxCDABE was cultured in either CA-MHB or RPMI+ as described for the MIC determination experiments. As in the MIC experiments, 180 μl of an approximately 5 × 10 5 CFU (~OD 600 = 0.002) culture was added to each experimental well of a 96-well plate containing 20 μl of the 10× stock of the desired drug, or 10 μl of a 20× stock of each drug for AZM + MIN combination experiments. Plates were incubated stationary at 37°C and sampled hourly for 13 h. At each timepoint, the Enspire Alpha multimode plate reader (PerkinElmer) was used to sequentially measure both the luminescence and OD 600 of each well. To control for alterations in luminescence due to cellular density changes the total luminescent signal was divided by the OD 600 value of the culture within each well. For the AZM + MIN combination experiments the luminescence/OD 600 values for each well were divided by the value obtained for the untreated control wells to calculate the percent translational activity of each data point. A line of additivity was calculated for the combination treatment by combining the percent change in translation activity of each drug in monotherapy. Combination values which fell below the line of additivity were considered to have a synergistic interaction.
Statistics
All statistical analysis was conducted in GraphPad prism 7. A twoway ANOVA was utilized to determine significant effects due to treatment with AZM and/or MIN where indicated. Tukey's multiple comparison test was used to determine significant differences between treatment groups. Statistical significance was defined as p value b.0500 with * ≤0.0500-0.0100, ** ≤0.0100-0.0010, *** ≤0.0010-0.0001, and **** ≤0.0001.
Results
AZM and MIN show reciprocal media-dependent inhibitory activities vs. MDR A. baumannii
Minimum inhibitory concentrations (MIC) of MIN and AZM against A. baumannii were determined in (a) a standard rich bacteriologic testing medium (cation-adjusted Mueller-Hinton broth, CA-MHB), or (b) the common tissue culture medium RPMI, which contains the physiological buffer bicarbonate anion (HCO 3 -). To ensure bacterial growth equivalency to CA-MHB, RPMI was supplemented with 10% Luria broth (LB), hereafter designated RMPI+. Four A. baumannii strains were examined: antibiotic-sensitive laboratory standard ATCC17978 and MDR clinical isolates AB5075, GNR175J and GNR0717. As shown in Table 1 , AZM had negligible activity against all four A. baumannii strains in standard CA-MHB (MIC 90 32 to 128 μg/ml), but potent activity against the bacteria in RPMI+ (MIC 0.25 to 2 μg/ml). Conversely, MIN had strong activity against all four strains in standard CA-MHB (MIC 90 0.25 to 4 μg/ml) yet lost all activity against the bacteria in RPMI+ (MIC 90 ≥ 256 μg/ml) ( Table 1) . Focusing on MDR A. baumannii strain AB5075, we quantified bacterial colony-forming units (CFU) to ascertain bactericidal activity. In CA-MHB (Fig. 1A and B) , MIN showed potent killing activity (MBC 99 = 1 μg/ml) whereas AZM was ineffective (MBC 99 N 32 μg/μl); conversely in RPMI+ ( Fig. 1D and E) , AZM was highly bactericidal (MBC 99 = 2.5 μg/ml) while MIN was completely inactive (MBC 99 N 64 μg/ml). Similar results were seen when RPMI was supplemented with 20% freshly isolated human blood instead of 10% LB ( Fig. 1G and H) , with complete killing of A. baumannii by AZM at 1 μg/ ml, but only partial killing of the bacterium at high MIN concentrations of 8 to 64 μg/ml.
AZM and MIN combinations have synergistic activity vs. MDR A. baumannii
Both MIN and AZM are bona fide bacterial translation inhibitors, with MIN (like other tetracyclines) binding to the 30S ribosomal subunit to block binding of aminoacyl-tRNA to the mRNA-ribosome complex [20] , and AZM (like other macrolides) binding to the 50S subunit to obstruct the nascent peptide exit tunnel and reshape the bacterial proteome [21] . The independent binding targets of the two drugs and the discordant media dependent activity profiles led us to explore the utility of combining both drugs to develop a condition-independent regimen for targeting translation in MDR A. baumannii. Indeed, used in combination, MIN and AZM interacted synergistically, as defined by a fractional inhibitory concentration index (FICI) of ≤0.5 [18] in both test media: CA-MHB (Fig. 1C , FICI = 0.38) and RPMI+ (Fig. 1F , FICI = 0.09). Combinations of AZM and MIN were also found to have synergistic bactericidal activity in 20% human blood, as measured via a fractional bactericidal concentration index (FBCI, [22] ) of ≤0.5 (Fig. 1I , FBCI = 0.50).
Media-dependent antibiotic activity of MIN and AZM is influenced by bicarbonate
We hypothesized the opposing media-dependent antibiotic activity profiles of MIN and AZM vs. A. baumannii could involve a differential response to HCO 3 -present in the tissue culture media but absent in the bacteriological media. We therefore titrated NaHCO 3 into bicarbonatefree RPMI+ medium to assess its impact on the activity of both AZM and MIN. Increasing the concentration of NaHCO 3 led to a marked reduction in the AZM MIC while simultaneously increasing the MIN MIC ( Fig. 2A) . When the concentration of each drug was held constant (MIN 2 μg/ml and AZM 1 μg/ml), a threshold level of 12 mM NaHCO 3 led to a dramatic increase in AZM bactericidal activity (Fig. 2B ) while abolishing MIN bactericidal activity (Fig. 2C) , a pattern maintained through the physiological HCO 3-serum concentration of~24 mM.
Therapeutic benefit of combined AZM and MIN in a murine model of A. baumannii pneumonia
Having identified potent synergy between AZM and MIN in vitro, we moved to assess the in vivo efficacy of adding AZM to MIN in a murine A. baumannii pneumonia model. Adult C57BL/6 mice were infected intratracheally with a lethal challenge dose of MDR A. baumannii AB5075 and treated 1 h and 24 h post infection with varying doses of AZM and MIN. The AZM dosages in mice were selected to approximate that used in human patients, with the maximum 50 mg/kg AZM in mice recapitulating the recommended 500-1000 mg patient dose [23] . Two concentrations of MIN were chosen that did not exceed the standard 200-400 mg daily dose limit in humans (6 mg/kg) [11, 24, 25] . The first dose was chosen to be ineffective as monotherapy (0.39 mg/kg), conferring no reductions in lung bacterial burden (Fig. 3A) nor survival advantage with 100% mortality (Fig. 3B) . The second MIN dose of 0.78 mg/kg was chosen to be suboptimal as monotherapy, with no changes in lung bacterial burdens (Fig. 3A) but providing an 80% survival rate (Fig. 3C) . AZM doses of 12.5, 25, 50 mg/kg alone had no effect on the lung bacterial burdens (Fig. 3A) , and even at the highest dose of 50 mg/kg provided no survival advantage ( Fig. 3B and C) . However, mice that received AZM in addition to the previously ineffective MIN dose of 0.39 mg/kg showed a dose-dependent reduction in their lung bacterial loads (Fig. 3A) , and a clear survival advantage with a survival rate increase from 0% with either drug alone to 80% when 50 mg/kg AZM was used in combination with MIN treatment (Fig. 3B) . Adding AZM to 0.78 mg/kg MIN significantly reduced lung bacterial loads in a dosedependent fashion (Fig. 3A) while also increasing the survival rate of the MIN-treated mice from 80% to 100% at the highest (50 mg/kg) AZM dose (Fig. 3C) .
Bacterial cytological profiling (BCP) demonstrates augmented translation inhibition in MDR A. baumannii upon AZM plus MIN cotreatment
To further explore the synergistic interaction between AZM and MIN, we employed BCP, a powerful technique that uses quantitative fluorescence microscopy to identify disrupted bacterial cellular pathways on a single cell level [19] . A characteristic signature of translation inhibition evident in BCP is formation of DNA toroids that arise due to changes in chromosome compaction when ribosome activity is disrupted [19] . In both CA-MHB and RPMI+, we identified drug concentrations in which neither AZM nor MIN inhibited MDR A. baumannii translation on their own, as confirmed by minimal toroid formation ( Fig. 4A and C) .
Extensive toroid formation was observed, however, when the two drugs were co-administered at these same concentrations ( Fig. 4A  and C) . In CA-MHB, visible toroids were seen in 2.2% of untreated A. baumannii cells, 2.8% of cells treatment with 0.15 μg/ml MIN, 4.2% of cells treated with 96 μg/ml AZM, and 34.0% of cells treated with 0.15 μg/ml MIN + 96 μg/ml AZM (Fig. 4B) . In RPMI+, visible toroids were seen in 0.3% of untreated A. baumannii cells, 4.5% of cells treatment with 50 μg/ml MIN, 2.5% of cells treated with 0.25 μg/ml AZM, and 27.2% of cells treated with 50 μg/ml MIN + 0.25 μg/ml AZM (Fig. 4D) . and 200 in at least 3 frames, with toroid nuclei for untreated and treated cultures in RPMI+. BCP images are representative of 3 independent experiments. Percent total toroid containing cells is combined data from 3 independent experiments for each media type. Scale bar = 2 μm. For panels (B) and (D), statistical significance was calculated using a twoway ANOVA with ** ≤0.01 and *** ≤0.001.
Nonoverlapping translation inhibition kinetics underlie AZM and MIN synergy vs. MDR A. baumannii
To better understand the dynamics of AZM and MIN translational inhibition synergy, we employed a reporter derivative of MDR A. baumannii (AB5075-luxCDBAE) that contains the full luciferase cassette and can independently synthesize both enzyme and substrate needed for luminescence. Intrinsic luminescence is lost upon translational inhibition as synthesis of the required components is blocked, and drug treatment effects can be determined kinetically on a cellular level as the ratio of luminescence signal per optical density (OD 600 ), thus controlling for bacterial replication. When used alone in CA-MHB, AZM-induced translation inhibition in A. baumannii was delayed, allowing for initial bacterial growth, but sustained once inhibition occurred throughout the remaining course of the experiment (Fig. 5A) . The late onset of AZM-associated translation inhibition, and its subsequent long-lasting effects, were even more pronounced in RPMI+, where sub-MIC concentrations of 1/4 and 1/2 the AZM MIC eventually inhibited A. baumannii translation despite allowing initial transcription and growth (Fig. 5D) . Conversely, MIN was found to robustly inhibit translation in CA-MHB even at sub-MIC concentrations (Fig. 5B ), but this inhibition was short-lived, and at concentrations of 1/16 and 1/8 the MIC, translation soon resumed (Fig. 5B) . The fast-acting but shortlived translational inhibition by MIN was even more pronounced in RPMI+, where concentrations of 1/64, 1/32 and 1/16 the MIC all permitted protein synthesis after initial inhibition (Fig. 5E) . To analyze the value of combining MIN + AZM against MDR A. baumannii, we calculated percent luminescence compared to untreated control at each time point. At sub-MIC concentrations for the individual drugs, combinations of MIN + AZM were both fast-acting and long-lasting compared to single drug treatments in both CA-MHB (Fig. 5C ) and RPMI+ (Fig. 5F ) media. Generating a line of additivity by combining the change in percent inhibition of each drug alone, MIN + AZM combination therapy surpassed the additive effects of the single drug treatments in both media conditions (Fig. 5C and F) .
AZM and MIN synergy against additional high-priority MDR bacterial pathogens
Having established clear synergism of AZM + MIN dual therapy vs. MDR A. baumannii, we examined the combination potential against other high priority MDR human pathogens: Gram-negative P. aeruginosa and K. pneumoniae and Gram-positive methicillinresistant Staphylococcus aureus (MRSA). As seen with A. baumannii, media-dependent conditional antibiotic activities of MIN (CA-MHB potency ≫ RPMI+ potency) and AZM (RPMI+ potency ≫ CA-MHB potency) were confirmed for all three additional species (Table 2) . For the Gram-negative pathogens, strong synergy was observed vs. MDR K. pneumonia in both CA-MHB (Fig. 6A , FICI = 0.38) and RPMI+10%LB (Fig. 6D , FICI = 0.19) while synergy against MDR P. aeruginosa was identified only in CA-MHB (Fig. 6B , FICI = 0.50) and fell short in RPMI + (Fig. 6E , FICI = 0.53). Of note, the two drugs synergized against MDR S. aureus in both CA-MHB (Fig. 6C , FICI = 0.31) and RPMI+ (Fig. 6F , FICI = 0.38) indicating AZM + MIN synergy is not restricted to Gram-negative pathogens. Future studies are required to confirm that such broad-spectrum synergy of AZM and MIN extends to in-vivo infection models.
Discussion
Under ideal circumstances, antimicrobial therapy would sufficiently reduce bacterial burden at the end of therapy to reduce the likelihood of relapse and the emergence of drug resistance. Therapies with conditionally independent activity profiles are desirable because efficient bacterial killing in vivo typically requires eliminating the pathogen from multiple host microenvironments. On their own, both AZM and MIN displayed media-dependent conditional activity, a potential limiting trait for their use in monotherapy. However, AZM + MIN combination therapy complemented the intrinsic inhibition profile seen with either drug alone, yielding a conditionally-independent synergistic therapy with efficacy against MDR A. baumannii in laboratory culture and a murine pneumonia model. The synergistic drug combination promoted enhanced translation inhibition kinetics, melding the fast-acting activity of MIN with the sustained inhibition of AZM to create a potent, longlasting, and efficacious antibiotic profile.
The AZM + MIN drug-drug interaction appears to represent a parallel pathway interaction, when the two drugs, often each having suboptimal activity against the same primary target, combine their activities to more effectively inhibit a bacterial system or biochemical pathway [26] [27] [28] , in this case protein translation at the ribosome. Both drugs have associated deficiencies as monotherapy. AZM activity is notably delayed due to its slow release from tissues [29] and a low rate of association with ribosomes [30] . Compared to AZM, the therapeutic window for MIN is shorter (half-life~12-16 h in humans) [31] and its bactericidal capacity has been brought into question [32, 33] . In combination, however, expedited MIN activity buys time for the slower acting, yet longer lasting, AZM-associated inhibition to occur. Furthermore, the media-dependent activity of each drug was complemented by the other, so that their synergistic activity was independent of media composition. And while we established parallel pathway synergy for MIN + AZM in translation inhibition kinetics, an important caveat of our study is that we cannot exclude the possibility of additional mechanisms of synergy such as compounding downstream effects on a tertiary target, or one drug acting to improve the bioavailability of the other [26] [27] [28] .
This study also highlights the benefit of investigating antibiotic activity in more than one medium condition to infer potential clinical efficacy and opportunities for synergistic therapy. Limitations of testing only the standard bacteriological medium (CA-MHB) have previously been illustrated [10, 34] , testing in a more physiologic tissue culturebased medium was also not fully predicative of in vivo efficacy as MIN is active in the murine pneumonia model despite little to no activity in RPMI+. One important compositional difference between the two media we have highlighted is the presence of the physiological buffer bicarbonate anion (HCO 3 -) in RPMI. HCO 3 -is an essential component of multiple biological processes in humans and its presence stimulates both transcriptional and translational changes in bacteria [35] , impacting antibiotic activity against numerous species when added to CA-MHB [34] . Recent work has linked HCO 3 -mediated effects on antibiotic activity to reductions in bacterial proton motive force [36] . While AZM activity is known to improve in response to a loss of proton motive force, indicating that AZM is not actively imported [37] , the entry of tetracyclines into the bacterial cell is an energy dependent process requiring active transport [38] . Enhanced macrolide activity against both Escherichia coli and Staphylococcus aureus have been reported in the presence of HCO 3 -due to the dissipation of the pH gradient required for a functioning proton motive force [34] . The loss of active transport renders the bacteria unable to export AZM leading to its intracellular accumulation, an effect which has previously been associated with enhanced AZM activity [10] .
In summary, the therapeutic potential of AZM and MIN combination therapy warrants clinical study as the two drugs were found to interact synergistically against MDR A. baumannii in all conditions and models examined in this study. This benefit may extend to other MDR pathogens, in particular MDR K. pneumoniae and MRSA. A limitation of our study at present is that future work is required to explore if MIN synergy is also found with other macrolides. Nevertheless, as both AZM and MIN are already FDA approved, readily available for use, and familiar to clinicians, the potential for clinical trials to determine the efficacy of the combinatorial therapy for A. baumannii is immediately at hand.
Author contributions
Drs. Dillon and Nizet had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of data analysis.
Study concept and design: Dillon, Sakoulas, Nizet.
Acquisition, analysis or interpretation of data: All authors. Laboratory experiments: Dillon, Holland, Tsunemoto, Hancock. Drafting of manuscript: Dillon, Nizet. Administrative, technical or material support: Tsunemoto, Pogliano. Statistical analysis: Dillon, Cornax. Critical revision of the manuscript for important intellectual content: All authors.
Declaration of Competing Interests
Dr. Pogliano owns stock in and receives consulting fees from Linnaeus Bioscience Inc. outside the submitted work. Dr. Sakoulas reports personal fees from The Medicines Company/Melinta Therapeutics, outside the submitted work. Dr. Nizet reports other from Cellics Therapeutics, grants and other from InhibRx, grants, personal fees and other from Cidara Therapeutics, personal fees from Iogen, Inc., personal fees from SutroVax, other from Centauri Therapeutics, all outside the submitted work. ND, MH, HT, BH and IC have no conflicts to disclose.
Funding/support
This is research was funded by the National Institutes of Health U01 AI124326 (JP, GS, VN) and U54 HD090259 (GS, VN). IC was supported by the UCSD Research Training Program for Veterinarians T32 OD017863.
Role of the funder/sponsor
The Funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
